Chen S-P, Fuh J-L, Lirng J-F, Chang F-C, Wang S-J
National Yang-Ming University School of Medicine, Taipei, Taiwan.
Neurology. 2006 Dec 26;67(12):2164-9. doi: 10.1212/01.wnl.0000249115.63436.6d.
To investigate the clinical pictures of patients with recurrent thunderclap headaches of unknown etiology and to field-test two relevant International Classification of Headache Disorders, 2nd edition (ICHD-II) criteria, i.e., primary thunderclap headache (Code 4.6) and benign (or reversible) angiopathy of the CNS (Code 6.7.3).
We prospectively recruited patients presenting with idiopathic recurrent thunderclap headaches from a hospital-based headache clinic. Detailed histories, neurologic examinations, and MRIs and magnetic resonance angiographies (MRAs) were performed in all patients to exclude secondary causes. Patients with cerebral vasoconstriction received serial MRA follow-up.
Fifty-six consecutive patients (51 female/5 male, mean age 49.6 +/- 9.8 [range 22 to 76] years) were enrolled. Segmental vasoconstriction (or benign CNS angiopathy) was found in 22 patients (39%). Thunderclap headache recurred in all patients with a median frequency of 0.7 times per day for a median period of 14 days (range 6 to 86 days). The median duration for each single attack was 3 hours. Most patients (84%) reported at least one trigger. Nimodipine effectively aborted further attacks in 83% of the treated patients. Headache attacks subsided within 3 months. Four patients (7%) developed ischemic complications. Patients with and without vasoconstriction based on MRA images were similar regarding demographics and headache profile. Except for the duration criterion, our patients generally mapped well into the proposed ICHD-II criteria.
This study suggests that the two diagnostic entities proposed by the ICHD-II may present different spectra of the same disorder. The distinct headache profile may help physicians quickly recognize this disabling headache disorder with risk of stroke and provide timely treatment.
研究病因不明的复发性霹雳样头痛患者的临床表现,并对国际头痛疾病分类第2版(ICHD-II)的两条相关标准进行实地测试,即原发性霹雳样头痛(编码4.6)和中枢神经系统良性(或可逆性)血管病(编码6.7.3)。
我们从一家医院的头痛门诊前瞻性招募了特发性复发性霹雳样头痛患者。对所有患者进行了详细的病史、神经系统检查以及磁共振成像(MRI)和磁共振血管造影(MRA),以排除继发性病因。脑血管收缩的患者接受了系列MRA随访。
共纳入56例连续患者(51例女性/5例男性,平均年龄49.6±9.8岁[范围22至76岁])。22例患者(39%)发现节段性血管收缩(或良性中枢神经系统血管病)。所有患者均出现霹雳样头痛复发,中位发作频率为每天0.7次,中位发作期为14天(范围6至86天)。单次发作的中位持续时间为3小时。大多数患者(84%)报告至少有一个诱发因素。尼莫地平使83%的治疗患者有效终止了进一步发作。头痛发作在3个月内消退。4例患者(7%)发生了缺血性并发症。根据MRA图像有或无血管收缩的患者在人口统计学和头痛特征方面相似。除持续时间标准外,我们的患者总体上与提议的ICHD-II标准相符。
本研究提示,ICHD-II提出的两个诊断实体可能代表同一疾病的不同谱型。独特的头痛特征可能有助于医生快速识别这种具有中风风险的致残性头痛疾病并及时进行治疗。